Abstract: TH-PO924
ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis
Session Information
- COVID-19: Vaccines and Outcomes ESRD/KTR
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Pongpirul, Krit, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
- Prasithsirikul, Wisit, Bamrasnaradura Infectious Disease Institute, Nonthaburi, Nonthaburi, Thailand
- Nopsopon, Tanawin, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
- Phutrakool, Phanupong, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
- Kantagowit, Piyawat, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
- Jongkaewwattana, Anan, National Center of Genetic Engineering and Biotechnology, Pathum Thani, Thailand
Background
This study aimed to evaluate the immunogenicity of two doses of ChAdOx1 nCoV-19 and the immune response post-COVID-19 infection in ESRD with HD patients.
Methods
The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method using Euroimmun.
Results
This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between one-shot ChAdOx1 nCoV-19 vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at one-month after one-shot vaccination and slightly dropped to 58.73% at 3-month follow-up, then was 92.06% at one-month after two-shot vaccination and reduced to 82.26% at 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at one-month post-recovery and 92.50% at 3-month follow-up.
Conclusion
This study established the immunogenicity of two-shot ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months.
Demographic Data of Participants
| Characteristics | Total | Vaccinated | Recovered |
| Participants | 109 | 63 | 46 |
| Age, year (mean ± SD) | 54.93 ± 15.28 | 57.63 ± 14.83 | 51.22 ± 15.26 |
| Hypertension | 89 (81.65%) | 56 (88.89%) | 33 (71.74%) |
| Diabetes mellitus | 49 (44.95%) | 33 (52.38%) | 16 (34.78%) |
| Coronary artery disease | 4 (3.67%) | 3 (4.76%) | 1 (2.17%) |
Data were presented as counts and percentages if not otherwise specified. SD: standard deviation.
Changes in anti-spike IgG in HD patients who received a single dose of ChAdOx1 and who recovered from COVID-19.
Funding
- Government Support – Non-U.S.